18/10/2025 01:11
|
Medical, Health & Aged Care
* With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%
* Global Phase 3 MANEUVER study demonstrated ongoing improvements in key...